Updates on managing Myleodysplastic Syndromes
This is a very scientific entry at Cancer Consultants.com. But if you want to research Myleodysplastic Syndromes, then here is some information.
Here's the introduction:
Source: CancerConsultants.com
Here's the introduction:
The myelodysplastic syndromes (MDS) are a collection of clonally-derived hematopoietic disorders typified by peripheral blood cytopenias, transfusion-dependency, and in a subset of patients, increased likelihood of transformation to acute myeloid leukemia (AML).1,2 This past decade has brought increased attention to MDS with the approval by the U.S. Food and Drug Administration of three MDS therapies, and a more complete understanding of these diseases on a molecular level. This year at the American Society of Hematology (ASH) 2007 annual meeting, presentations focused on the implications and management of MDS- and treatment-related cytopenias; results of clinical trials of hypomethylating agents, including the first prospectively-acquired survival data; and extension of the potential applicability of immunomodulatory drugs.
Source: CancerConsultants.com
